Survodutide, a glucagon/GLP-1 dual agonist, met its primary endpoint of histological improvement in MASH at 48 weeks and also demonstrated a statistically significant improvement in fibrosis, a secondary endpoint
Fremaux, J
Levity helps people take control of their health with medically supervised weight loss solutions, including GLP-1 medications like Ozempic and Compounded* Liraglutide with B12
Most of these medications are injections, with dosing schedules that vary depending on the brand and specific treatment plan
Low diversity and dysbiosis can raise inflammatory markers that not only make fat loss slower but also make surface irregularities on the skin more prominent
If there is significant hanging skin, especially after prior obesity or very large weight loss, non-surgical tightening may improve skin quality and modest laxity, but it cannot remove large amounts of extra skin